Effects of biologic therapy on novel indices of lung inhomogeneity in patients with severe type-2 high asthma.

ABSTRACT:

Introduction/aim

Lung inhomogeneity measures obtained using computed cardiopulmonography (CCP) are sensitive to small-airways disease. Here, we assessed changes in lung inhomogeneity in patients with type-2 high asthma treated with biological therapy and explored the relationship between inhomogeneity measures and conventional asthma disease markers.

Methods

This was an observational study of 91 severe type-2 high asthma patients recruited from a tertiary asthma clinic, of whom 67 subsequently started anti-IL5 or anti-IL5R biologics. Patients were evaluated at baseline and, 54 of those commencing biologics, at their fourth injection with either mepolizumab or benralizumab. Assessments included prebronchodilator and postbronchodilator CCP and spirometry, and measurements of b

SUBMITTER: Alamoudi A 

PROVIDER: S-EPMC11808925 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature